Key result
Temporary placement of paclitaxel or rapamycin-eluting stents improved LOSP, 5-mBH, and cardia patency, and reduced inflammatory reactions and scarring compared to bare stents (p<0.05).
Why the study?
Does temporary placement of paclitaxel or rapamycin-eluting stents reduce stenting-induced inflammatory reaction and scarring compared to bare stents in dog models of benign cardia stricture?
RCT (n=80)
randomly divided
Does temporary placement of paclitaxel or rapamycin-eluting stents reduce stenting-induced inflammatory reaction and scarring compared to bare stents in dog models of benign cardia stricture?
Temporary placement of paclitaxel or rapamycin-eluting stents reduces inflammation and scarring compared to bare stents in a canine model of benign cardia stricture.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for drug-eluting stents in benign cardia stricture; human trials needed before clinical consideration.
BACKGROUND/AIMS: To investigate whether temporary placement of a paclitaxel or rapamycin eluting stent is more effective to reduce stenting induced inflammatory reaction and scaring than a bared stent in benign cardia stricture models. MATERIALS AND METHODS: Eighty dog models of stricture were randomly divided into a control group (CG, n=20, no stent insertion), a bare stent group (BSG, n=20), a paclitaxel eluting (Pacl-ESG, n=20) and a rapamycin eluting stent group (Rapa-ESG, n=20), with one-week stent retention. Lower-oesophageal-sphincter pressure (LOSP), 5-minute barium height (5-mBH) and cardia diameter were assessed before, immediately after the procedure, and regularly for 6 months. Five dogs in each group were euthanized for histological examination at each follow-up assessment. RESULTS: Stent insertion was well tolerated, with similar migration rates in three groups. At 6 months, LOSP and 5-mBH improved in Pacl-ESG and Rapa-ESG compared to BSG (p<0.05), with no difference between Pacl-ESG and Rapa-ESG (p>0.05). Cardia kept more patency in the Pacl-ESG and Rapa-ESG than in BSG (p<0.05). Reduced peak inflammatory reactions and scarring occurred in the Pacl-ESG and Rapa-ESG compared to BSG (p<0.05), with a similar outcome in the Pacl-ESG and Rapa-ESG (p>0.05). CONCLUSION: Paclitaxel or rapamycin-eluting stents insertion led to better outcomes than bare stents in benign cardia stricture models.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2015) conducted an RCT in benign cardia stricture (n=80). Paclitaxel or rapamycin-eluting stent vs. Bare stent and no stent was evaluated on Lower-oesophageal-sphincter pressure (LOSP), 5-minute barium height (5-mBH), and cardia diameter (p=<0.05). Temporary placement of paclitaxel or rapamycin-eluting stents improved LOSP, 5-mBH, and cardia patency, and reduced inflammatory reactions and scarring compared to bare stents (p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: